Did you look at the new trial at all? 50% increase in efficiency (in vitro not yet in humans) so it is not just for cardiovascular protection…. This is why I bring it to the attention to the lynch mob here!
Up to you if you choose to watch the progress of the trials there…. I will be that’s for sure
Once again Bisantrene has reached such high levels of cancer killing in vitro and all data from years ago!! That’s great Mason super exciting indeed!!
Seems like they pulled the pin on phase 2 trials with R110 for known reasons here now wonder how investors feel about all the money spent on those trials?? Now I know the spin will now be “but those trials helped us to make the decision on R220” blah blah…. So the fact stands even with all this data from the 80s the first trials haven’t been picked up by BP…
Now we look at the R220 formula with the IP protected for 20 years…. What stops another company from developing their own Bisantrene formula from here?? This is a genuine question as I am not sure if RAC owns Bisantrene outright for their own….. If RAC does this is a great big tick of risk removal for me!
Look once AGAIN I am not stating RAC is not onto a winner here…. Just asking questions and having discussions which I feel are insightful for new investors!
RAC Price at posting:
$1.83 Sentiment: None Disclosure: Not Held
(20min delay)